Condition: Lung Cancer · Extensive-stage Small-cell Lung Cancer · Sponsor: Sichuan University
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung cancer.
This description comes directly from the study's public registry record.
Min, Yu, MD · 02885423571 · yuminisagoodgirl@163.com
You, Lu, MD · 02885423571 · radyoulu@hotmail.com
Always discuss trial participation with your own doctor first.
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06217757